Chemical Compounds
Gefitinib
100%
Small Interfering RNA
87%
Silencing RNA
81%
Oncogenic
44%
Tyrosine Kinase Inhibitor
43%
Puromycin
43%
Cell Viability
31%
Tyrosine
28%
Protein
25%
Resistance
19%
Medicine & Life Sciences
Hepatocellular Carcinoma
50%
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one
50%
Survival
34%
Growth
31%
Small Interfering RNA
30%
Gefitinib
22%
Neoplasms
20%
Gene Expression Profiling
18%
Proto-Oncogene Proteins c-met
12%
Puromycin
12%
Hepatocyte Growth Factor
10%
Receptor Protein-Tyrosine Kinases
9%
Phosphoric Monoester Hydrolases
9%
Phosphatidylinositol 3-Kinases
8%
Oncogenes
8%
Protein-Tyrosine Kinases
8%
In Vitro Techniques
7%
Therapeutic Uses
7%
Therapeutics
7%
Phosphotransferases
6%
Cell Survival
6%
Proteins
6%
Kinetics
6%
Up-Regulation
6%
Clinical Trials
5%
Neoplasm Metastasis
5%
Apoptosis
5%
Cell Line
5%
Agriculture & Biology
hepatoma
68%
neoplasms
48%
therapeutics
27%
phosphotransferases (kinases)
23%
small interfering RNA
20%
cells
17%
hepatocyte growth factor receptor
16%
tyrosine
16%
hepatocyte growth factor
13%
phosphatidylinositol 3-kinase
11%
metastasis
11%
puromycin
11%
oncogenes
11%
gene expression
10%
prognosis
10%
clinical trials
9%
in vitro studies
8%
cell viability
8%
apoptosis
8%
protein synthesis
6%
cell lines
6%
screening
6%
receptors
6%
kinetics
5%